Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05099003 | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 4 | Sep 30, 2026 | clinicaltrials |
| NCT05298995 | GD2-CAR T Cells for Pediatric Brain Tumours | recruiting | Phase 1 | 54 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05370807 | A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma(RegoMel) | active not recruiting | Phase 2 | 48 | Universitair Ziekenhuis BrusselOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05378763 | A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations(PINNACLE) | suspended | Phase 3 | 268 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05413798 | Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa | recruiting | N/A | 300 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05414357 | Impact of Sleep Disturbance on Cognition and Quality of Life in Breast Cancer(ICANSLEEP) | recruiting | N/A | 75 | Centre Francois BaclesseOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05422794 | Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer | recruiting | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05432804 | Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | recruiting | Phase 1 / Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05440409 | CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL | completed | — | 57 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05442515 | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 130 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05519085 | A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(SUCCESSOR-1) | recruiting | Phase 3 | 810 | CelgeneINDUSTRY | 29 | Sep 30, 2026 | clinicaltrials |
| NCT05521698 | A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer | recruiting | Phase 1 | 80 | University of Wisconsin, MadisonOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05525858 | KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II(KOSMOSII) | active not recruiting | — | 1,000 | Seoul National University Bundang HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05534646 | Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc | recruiting | Phase 2 | 116 | Edwin Posadas, MDOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05611931 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma(XPORT-EC-042) | active not recruiting | Phase 3 | 257 | Karyopharm Therapeutics IncINDUSTRY | 17 | Sep 30, 2026 | clinicaltrials |
| NCT05642195 | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer | suspended | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05708703 | Assessing the Time Demands of Cancer | active not recruiting | — | 78 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05715684 | Patient-Centered Surgical Prehabilitation(Prehab) | recruiting | N/A | 25 | Brigham and Women's HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05730036 | A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma(LINKER-MM3) | recruiting | Phase 3 | 410 | Regeneron PharmaceuticalsINDUSTRY | 18 | Sep 30, 2026 | clinicaltrials |
| NCT05739331 | Augmented Endobronchial Ultrasound (EBUS-TBNA) With Artificial Intelligence | recruiting | — | 50 | Norwegian University of Science and TechnologyOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05739942 | Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma | active not recruiting | Phase 1 | 42 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 30, 2026 | clinicaltrials |
| NCT05742204 | Plasma Proteomic Biomarkers for Early Diagnosis of Lung Cancer | active not recruiting | — | 3,700 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05779605 | Telerehabilitation in Hemato-oncological Survivors(Tele@home) | completed | N/A | 80 | Brno University HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05868226 | PRE-ISPY Phase I/II Oncology Platform Program(PRE-ISPY) | recruiting | Phase 1 / Phase 2 | 280 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05873686 | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 140 | Nuvectis Pharma, Inc.INDUSTRY | 2 | Sep 30, 2026 | clinicaltrials |
| NCT05899361 | A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest | completed | N/A | 7 | Brigham and Women's HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05954910 | A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma | active not recruiting | — | 1,000 | Hoffmann-La RocheINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05969002 | Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias | completed | — | 10 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05987189 | Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung | active not recruiting | — | 2,000 | Hummingbird DiagnosticsINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05987241 | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | recruiting | Phase 2 / Phase 3 | 992 | National Cancer Institute (NCI)NIH | 2 | Sep 30, 2026 | clinicaltrials |
| NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | recruiting | Phase 3 | 3,680 | National Cancer Institute (NCI)NIH | 2 | Sep 30, 2026 | clinicaltrials |
| NCT06077500 | DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer(DAREONᵀᴹ-8) | active not recruiting | Phase 1 | 46 | Boehringer IngelheimINDUSTRY | 8 | Sep 30, 2026 | clinicaltrials |
| NCT06079671 | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)(eVOLVECervical) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 19 | Sep 30, 2026 | clinicaltrials |
| NCT06081673 | Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC | active not recruiting | Phase 2 | 72 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06096844 | Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | recruiting | Phase 3 | 304 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06105684 | Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer | recruiting | Phase 2 | 40 | University of Alabama at BirminghamOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06128785 | Electroacupuncture (EA) Promotes Gastrointestinal Functional Recovery After Radical Colorectal Cancer Surgery | completed | N/A | 305 | Shanghai Yueyang Integrated Medicine HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06129864 | A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy(eVOLVE-HNSCC) | recruiting | Phase 3 | 1,145 | AstraZenecaINDUSTRY | 23 | Sep 30, 2026 | clinicaltrials |
| NCT06147037 | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | active not recruiting | Phase 1 | 13 | AstraZenecaINDUSTRY | 2 | Sep 30, 2026 | clinicaltrials |
| NCT06197672 | Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant | suspended | Phase 1 | 30 | Huda SalmanOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06203119 | Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe | completed | Phase 1 | 18 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06206837 | A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. | active not recruiting | Phase 1 / Phase 2 | 71 | PfizerINDUSTRY | 8 | Sep 30, 2026 | clinicaltrials |
| NCT06219941 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | recruiting | Phase 2 | 226 | AstraZenecaINDUSTRY | 14 | Sep 30, 2026 | clinicaltrials |
| NCT06245876 | Lung EpiCheck Biomarkers Development Study | completed | — | 2,132 | Nucleix Ltd.INDUSTRY | 4 | Sep 30, 2026 | clinicaltrials |
| NCT06258525 | SAMe in Prevention of Oxaliplatin-associated Liver Injury | not yet recruiting | Phase 2 | 30 | Cedars-Sinai Medical CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06275919 | Regorafenib for Recurrent Meningioma (MIRAGE Trial)(MIRAGE) | recruiting | Phase 2 | 104 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06303193 | Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms | recruiting | Phase 1 / Phase 2 | 160 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06305247 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 36 | IpsenINDUSTRY | 3 | Sep 30, 2026 | clinicaltrials |
Data updated 2 hours agoSource updated Sep 30, 2026source: clinicaltrials